OXB is one of the original pioneers in gene and cell therapy. We’re already collaborating with some of the world’s most innovative pharmaceutical and biotechnology companies towards a shared mission: to make cell and gene therapy a universally accessible clinical option.
0+
Over 30 years of experience
~0
Successful GMP batches
~0
Global active clients
0+
Countries with approved products using our vectors
State-of-the-art facilities in the UK, US, and France
We can accommodate a variety of vector types, processes and batch volumes across our suites in the UK, US, and France. Our state-of-the-art, automated fill-finish facilities package vectors ready for clinical or commercial use. With the addition of the FDA-approved Durham, NC site (drug substance + fill-finish), OXB now offers end-to-end US capabilities supporting late-stage and commercial programmes, particularly in AAV.